Erste Group Bank Brokers Increase Earnings Estimates for LLY

Eli Lilly and Company (NYSE:LLY) – Research analysts at Erste Group Bank lifted their FY2026 earnings per share (EPS) estimates for Eli Lilly and Company in a report released on Friday, June 5th. Erste Group Bank analyst H. Engel now expects that the company will post earnings of $36.35 per share for the year, up from their prior estimate of $36.30. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $35.80 per share.

Several other analysts also recently issued reports on LLY. Barclays upped their price objective on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Monday, May 4th. Truist Financial restated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. HSBC downgraded Eli Lilly and Company from a “hold” rating to a “reduce” rating and reduced their price objective for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Jefferies Financial Group upped their price objective on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,227.74.

Eli Lilly and Company Stock Down 0.5%

Shares of NYSE:LLY opened at $1,138.78 on Thursday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,182.73. The stock’s fifty day simple moving average is $989.96 and its 200-day simple moving average is $1,015.14. The company has a market capitalization of $1.07 trillion, a P/E ratio of 40.45, a P/E/G ratio of 1.25 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the previous year, the business earned $3.34 earnings per share. Eli Lilly and Company’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS.

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors have recently added to or reduced their stakes in the business. Curry Webb Wealth Management LLC acquired a new position in Eli Lilly and Company in the first quarter valued at $1,974,000. FAS Wealth Partners Inc. increased its stake in Eli Lilly and Company by 3.5% in the first quarter. FAS Wealth Partners Inc. now owns 10,415 shares of the company’s stock valued at $9,579,000 after purchasing an additional 350 shares during the last quarter. Rathbones Group PLC increased its stake in Eli Lilly and Company by 6.6% in the first quarter. Rathbones Group PLC now owns 418,036 shares of the company’s stock valued at $384,497,000 after purchasing an additional 25,882 shares during the last quarter. Farmers National Bank increased its stake in Eli Lilly and Company by 0.4% in the first quarter. Farmers National Bank now owns 4,472 shares of the company’s stock valued at $4,113,000 after purchasing an additional 16 shares during the last quarter. Finally, Seven Fleet Capital Management LP acquired a new position in Eli Lilly and Company in the first quarter valued at $662,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date was Friday, May 15th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA approved extended every-8-weeks maintenance dosing for EBGLYSS, improving convenience and potentially boosting adoption in Lilly’s dermatology business.
• Positive Sentiment: Reuters reported that Lilly is still viewed as the leader in the fast-growing obesity-drug market, even as rivals rush into the space, reinforcing confidence in its competitive moat. Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
• Positive Sentiment: Recent coverage also highlighted positive Phase 3 data for retatrutide and favorable Foundayo (orforglipron) weight-loss results, keeping investor enthusiasm high around Lilly’s obesity pipeline.
• Positive Sentiment: Jefferies raised its price target on LLY to $1,350 and reiterated a Buy rating, signaling continued analyst confidence in the stock’s runway. Is Eli Lilly and Company (LLY) One of the 10 Best Dividend Stocks to Buy According to D. E. Shaw?
• Positive Sentiment: Lilly also announced a new Alzheimer’s collaboration with AlzeCure, expanding its neuroscience pipeline and adding another potential long-term growth opportunity.
• Neutral Sentiment: Several articles were commentary pieces or portfolio lists that reinforce Lilly’s reputation as a high-quality defensive growth name, but they do not add materially new fundamental information.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.